Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
L275075-25μg | 25μg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $1,030.90 | |
L275075-50μg | 50μg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $1,854.90 |
Potent, selective CysLT 1 and CysLT 2 receptor agonist
Synonyms | DB11858 | Glycine, N-(S-(1-(4-carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraenyl)-L-cysteinyl)-, (R-(R*,S*-(E,E,Z,Z)))- | Glycine, S-[(1R,2E,4E,6Z,9Z)-1-[(1S)-4-carboxy-1-hydroxybutyl]-2,4,6,9-pentadecatetraen-1-yl]-L-cysteinyl- | Q647917 | S-((1R,2E,4E,6 |
---|---|
Specifications & Purity | Moligand™, ≥97%, 100 ug/mL in ethanol |
Biochemical and Physiological Mechanisms | Potent, selective CysLT 1 and CysLT 2 receptor agonist (EC 50 values are 1.12 and 0.99 nM, respectively. Induces bronchoconstriction and vasoconstriction. Active in vivo and in vitro . |
Storage Temp | Protected from light,Argon charged,Store at -80°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | AGONIST |
Mechanism of action | Agonist of CysLT 1 receptor;Agonist of CysLT 2 receptor;Agonist of GPR17 |
Note | Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -80°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description | Leukotriene D4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A) produced by the metabolism of LTC4 by γ-glutamyl transpeptidase. Leukotriene D4 is the first cysteinyl-leukotriene metabolite of LTC4. Leukotriene D4-induced bronchoconstriction and enhanced vascular permeability contribute to the pathogenesis of asthma and acute hypersensitivity. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|---|---|---|---|---|---|---|
Cysteinyl leukotriene receptor 1 antagonist | ANTAGONIST | ALA1798 | Cysteinyl leukotriene receptor 1 | SINGLE PROTEIN | Homo sapiens | DailyMed: [1] | |
Cysteinyl leukotriene receptor 1 antagonist | ANTAGONIST | ALA1798 | Cysteinyl leukotriene receptor 1 | SINGLE PROTEIN | Homo sapiens | DailyMed: [1] | |
Cysteinyl leukotriene receptor 1 antagonist | ANTAGONIST | ALA1798 | Cysteinyl leukotriene receptor 1 | SINGLE PROTEIN | Homo sapiens | ||
Cysteinyl leukotriene receptor 1 antagonist | ANTAGONIST | ALA1798 | Cysteinyl leukotriene receptor 1 | SINGLE PROTEIN | Homo sapiens |
IUPAC Name | (5S,6R,7E,9E,11Z,14Z)-6-[(2R)-2-amino-3-(carboxymethylamino)-3-oxopropyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid |
---|---|
INCHI | InChI=1S/C25H40N2O6S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-22(21(28)15-14-17-23(29)30)34-19-20(26)25(33)27-18-24(31)32/h6-7,9-13,16,20-22,28H,2-5,8,14-15,17-19,26H2,1H3,(H,27,33)(H,29,30)(H,31,32)/b7-6-,10-9-,12-11+,16-13+/t20-,21-,22+/m0/s1 |
InChi Key | YEESKJGWJFYOOK-IJHYULJSSA-N |
Canonical SMILES | CCCCCC=CCC=CC=CC=CC(C(CCCC(=O)O)O)SCC(C(=O)NCC(=O)O)N |
Isomeric SMILES | CCCCC/C=C\C/C=C\C=C\C=C\[C@H]([C@H](CCCC(=O)O)O)SC[C@@H](C(=O)NCC(=O)O)N |
PubChem CID | 5280878 |
Molecular Weight | 496.66 |
Find and download the COA for your product by matching the lot number on the packaging.
6 results found
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
Certificate of Analysis | Sep 05, 2024 | L275075 | |
Certificate of Analysis | Sep 05, 2024 | L275075 | |
Certificate of Analysis | Oct 21, 2022 | L275075 | |
Certificate of Analysis | Oct 20, 2022 | L275075 | |
Certificate of Analysis | Oct 20, 2022 | L275075 | |
Certificate of Analysis | Sep 09, 2022 | L275075 |
Solubility | DMF: 50 mg/ml;DMSO: 50 mg/ml;Ethanol: 1 mg/ml;PBS pH 7.2: >100 µg/ml |
---|---|
Sensitivity | Light sensitive&Air sensitive |
Pictogram(s) | GHS07, GHS02 |
---|---|
Signal | Danger |
Hazard Statements | H315:Causes skin irritation H319:Causes serious eye irritation H335:May cause respiratory irritation |
Precautionary Statements | P261:Avoid breathing dust/fume/gas/mist/vapors/spray. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. |
1. Lu Geng, Zhou Jiawei, Yang Ting, Li Jin, Jiang Xinrui, Zhang Wenjun, Gu Shuangshuang, Wang Jun. (2022) Landscape of Metabolic Fingerprinting for Diagnosis and Risk Stratification of Sepsis. Frontiers in Immunology, 13 [PMID:35663956] [10.3389/fimmu.2022.883628] |
1. Lu Geng, Zhou Jiawei, Yang Ting, Li Jin, Jiang Xinrui, Zhang Wenjun, Gu Shuangshuang, Wang Jun. (2022) Landscape of Metabolic Fingerprinting for Diagnosis and Risk Stratification of Sepsis. Frontiers in Immunology, 13 [PMID:35663956] [10.3389/fimmu.2022.883628] |